Compare Stocks: TNXP, ACRS, DBVT, and PHAR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.50 +1.9%	$5.79	$1.74 ▼ $6.60	$769.03M	0.79	2.40 million shs	4.69 million shs
DBVT DBV Technologies	$12.35 -1.3%	$13.86	$8.85 ▼ $26.18	$776.54M	-0.95	279,196 shs	137,641 shs
PHAR Pharming Group	$10.55 -2.1%	$11.71	$9.62 ▼ $21.34	$746.71M	0.01	17,814 shs	7,853 shs
TNXP Tonix Pharmaceuticals	$10.87 -4.8%	$11.99	$9.40 ▼ $28.42	$186.43M	1.74	402,583 shs	807,907 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+3.38%	-13.11%	+22.22%	+203.87%
DBVT DBV Technologies	0.00%	+4.22%	-13.27%	-20.48%	+26.73%
PHAR Pharming Group	0.00%	-5.89%	-9.67%	-16.83%	-27.74%
TNXP Tonix Pharmaceuticals	0.00%	-8.42%	-12.27%	-9.49%	-60.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.50 +1.9%	$5.79	$1.74 ▼ $6.60	$769.03M	0.79	2.40 million shs	4.69 million shs
DBVT DBV Technologies	$12.35 -1.3%	$13.86	$8.85 ▼ $26.18	$776.54M	-0.95	279,196 shs	137,641 shs
PHAR Pharming Group	$10.55 -2.1%	$11.71	$9.62 ▼ $21.34	$746.71M	0.01	17,814 shs	7,853 shs
TNXP Tonix Pharmaceuticals	$10.87 -4.8%	$11.99	$9.40 ▼ $28.42	$186.43M	1.74	402,583 shs	807,907 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	+3.38%	-13.11%	+22.22%	+203.87%
DBVT DBV Technologies	0.00%	+4.22%	-13.27%	-20.48%	+26.73%
PHAR Pharming Group	0.00%	-5.89%	-9.67%	-16.83%	-27.74%
TNXP Tonix Pharmaceuticals	0.00%	-8.42%	-12.27%	-9.49%	-60.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$11.33	106.06% Upside
DBVT DBV Technologies	2.57	Moderate Buy	$48.50	292.71% Upside
PHAR Pharming Group	2.20	Hold	$38.67	266.51% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	125.39% Upside

Current Analyst Ratings Breakdown

Latest TNXP, ACRS, DBVT, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/10/2026	DBVT DBV Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/1/2026	ACRS Aclaris Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	DBVT DBV Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	98.21	N/A	N/A	$0.85 per share	6.47
DBVT DBV Technologies	$5.64M	137.69	N/A	N/A	$4.20 per share	2.94
PHAR Pharming Group	$376.13M	1.99	$0.20 per share	52.61	$3.95 per share	2.67
TNXP Tonix Pharmaceuticals	$13.11M	14.22	N/A	N/A	$19.17 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
DBVT DBV Technologies	-$146.95M	-$3.51	N/A	N/A	N/A	-3,506.53%	-119.33%	-84.43%	10/28/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	87.92	42.20	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest TNXP, ACRS, DBVT, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
DBVT DBV Technologies	N/A	3.72	3.72
PHAR Pharming Group	0.34	3.01	2.31
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
DBVT DBV Technologies	71.74%
PHAR Pharming Group	0.03%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
DBVT DBV Technologies	1.06%
PHAR Pharming Group	2.07%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	73	139.82 million	133.11 million	Optionable
DBVT DBV Technologies	161	62.88 million	62.21 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable
TNXP Tonix Pharmaceuticals	142	17.15 million	16.81 million	Not Optionable

TNXP, ACRS, DBVT, and PHAR Headlines

Recent News About These Companies

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)

September 16, 2026 | theglobeandmail.com

Tonix Pharmaceuticals Holding Corp. (TNXP)

September 15, 2026 | finance.yahoo.com

Zacks Research Issues Positive Estimate for TNXP Earnings

September 12, 2026 | americanbankingnews.com

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

September 11, 2026 | marketbeat.com

Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst

September 10, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Tyra Bioscience (TYRA) and Becton Dickinson (BDX)

September 9, 2026 | theglobeandmail.com

Tonix Names Englese Chief Commercial Officer To Expand TONMYA Reach

September 9, 2026 | rttnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Share Price Passes Above 200-Day Moving Average - Here's Why

September 9, 2026 | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving Average - What's Next?

September 9, 2026 | marketbeat.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | finance.yahoo.com

Tonix Pharma Appoints New Chief Commercial Officer

September 8, 2026 | tipranks.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | globenewswire.com

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

September 2, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

September 2, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

September 2, 2026 | globenewswire.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares

September 1, 2026 | insidertrades.com

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock

August 31, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen

August 29, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Bagger Acquires 1,000 Shares

August 25, 2026 | insidertrades.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) Director Purchases $12,600.00 in Stock

August 24, 2026 | marketbeat.com

Tonix Pharma Names CEO Seth Lederman Interim CMO

August 18, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ACRS, DBVT, and PHAR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.50 +0.10 (+1.85%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.38 -0.12 (-2.11%)

As of 09/18/2026 07:30 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

DBV Technologies NASDAQ:DBVT

$12.35 -0.16 (-1.28%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.35 0.00 (0.00%)

As of 09/18/2026 04:10 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Pharming Group NASDAQ:PHAR

$10.55 -0.23 (-2.13%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.60 +0.05 (+0.47%)

As of 09/18/2026 04:10 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Tonix Pharmaceuticals NASDAQ:TNXP

$10.87 -0.55 (-4.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.96 +0.09 (+0.78%)

As of 09/18/2026 07:34 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, ACRS, DBVT, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, ACRS, DBVT, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, ACRS, DBVT, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ACRS, DBVT, and PHAR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Pharming Group NASDAQ:PHAR

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, ACRS, DBVT, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, ACRS, DBVT, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, ACRS, DBVT, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ACRS, DBVT, and PHAR Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

DBV Technologies NASDAQ:DBVT

Pharming Group NASDAQ:PHAR

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools